EVALUATION OF THE POSSIBLE ADVERSE EFFECTS OF ZANTHOXYLUM NARANJILLO GRISEB IN A CHRONIC PHASE STUDY (6 MONTHS) CARRIED OUT DURING PRECLINICAL TRIALS

Zanthoxylum species with universal distribution have shown large antiinflammatory, analgesic and antithermic activities (Kato et al., 1995). However, concerning to toxicity, there are very few reports in the specific literature (Hong et al., 1993; Chen, 1994).

The present study had as objective to determine the preclinical toxicity of high extract doses used for chronic phase treatment over a period of six months.

The treated animal group received the extract of Zanthoxylum naranjillo Griseb at the doses of 15 mg/kg and 150 mg/kg.
Seric parameters quantified were: glucose, cholesterol, triglycerides, proteins, albumin, billirubins, alkaline phosphatase (ALP), gama- glutamiltransferase (GGT), aspartate-aminotransaminase (AST-GOT), alanine-aminotransaminase (ALT-GPT), urea, creatinine, uric acid, red and white blood cells, prothrombin, thromboplastin, and platelet.
Statistics were by Nemenyi test (Sachs, 1974).

Results show that the extract has no demonstrable toxic side effects for the dose studied and is qualified for further steps of toxicological validation.

II WOCMAP Congress Medicinal and Aromatic Plants, Part 2: Pharmacognosy, Pharmacology, Phytomedicine, Toxicology

E.R. Rodrigues, A.H.P. Pedrazzi, J.K. Bastos, A. Zanardo Filho, J.J. Franco

Medical Plants, Zanthoxylum naranjillo, Toxicity study, Preclinical, Chronic phase, Clinical Chemistry

https://doi.org/10.17660/ActaHortic.1999.501.8